Arcus Biosciences Future Growth
Future criteria checks 2/6
Arcus Biosciences is forecast to grow earnings and revenue by 8.9% and 21.5% per annum respectively. EPS is expected to grow by 15% per annum. Return on equity is forecast to be -94.1% in 3 years.
Key information
8.9%
Earnings growth rate
15.0%
EPS growth rate
Biotechs earnings growth | 27.9% |
Revenue growth rate | 21.5% |
Future return on equity | -94.1% |
Analyst coverage | Good |
Last updated | 15 Oct 2024 |
Recent future growth updates
Recent updates
Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones
Sep 23Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business
Aug 19Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO
May 15Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts
May 13Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money
May 10We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
Feb 22Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Dec 18Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Dec 15Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Nov 20Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Aug 29Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates
Jun 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk
May 05Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17
Nov 02Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers
May 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 261 | -385 | -212 | -164 | 8 |
12/31/2025 | 207 | -388 | -445 | -436 | 9 |
12/31/2024 | 253 | -281 | -195 | -233 | 9 |
6/30/2024 | 247 | -249 | -267 | -247 | N/A |
3/31/2024 | 237 | -231 | -235 | -210 | N/A |
12/31/2023 | 117 | -307 | -330 | -306 | N/A |
9/30/2023 | 120 | -293 | -306 | -288 | N/A |
6/30/2023 | 121 | -287 | -316 | -306 | N/A |
3/31/2023 | 119 | -279 | -326 | -314 | N/A |
12/31/2022 | 112 | -267 | 426 | 438 | N/A |
9/30/2022 | 433 | 80 | 426 | 446 | N/A |
6/30/2022 | 409 | 67 | 447 | 473 | N/A |
3/31/2022 | 392 | 58 | 439 | 464 | N/A |
12/31/2021 | 383 | 53 | -282 | -256 | N/A |
9/30/2021 | 38 | -278 | -263 | -244 | N/A |
6/30/2021 | 93 | -199 | 14 | 26 | N/A |
3/31/2021 | 85 | -168 | 70 | 76 | N/A |
12/31/2020 | 78 | -123 | 108 | 111 | N/A |
9/30/2020 | 78 | -88 | 150 | 152 | N/A |
6/30/2020 | 15 | -112 | -93 | -92 | N/A |
3/31/2020 | 15 | -95 | -89 | -88 | N/A |
12/31/2019 | 15 | -85 | -75 | -73 | N/A |
9/30/2019 | 7 | -80 | -73 | -71 | N/A |
6/30/2019 | 9 | -69 | -58 | -55 | N/A |
3/31/2019 | 9 | -54 | -50 | -47 | N/A |
12/31/2018 | 8 | -50 | -47 | -43 | N/A |
9/30/2018 | 8 | -51 | -24 | -20 | N/A |
6/30/2018 | 4 | -63 | -36 | -33 | N/A |
3/31/2018 | 3 | -59 | N/A | -29 | N/A |
12/31/2017 | 1 | -53 | N/A | -25 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RCUS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RCUS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RCUS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RCUS's revenue (21.5% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: RCUS's revenue (21.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RCUS is forecast to be unprofitable in 3 years.